SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : The Epic American Credit and Bond Bubble Laboratory
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: GST who wrote (36190)7/17/2005 3:04:28 PM
From: Henry Niman  Read Replies (1) of 110194
 
There are two major targets for FDA antivirals. One is neuramindase (NA) which is targeted by Tamiflu and Relenza. The second is the M2 gene targeted by Amantadine and Rimantadine.

There is at least one instance of Tamiflu resistance being reported in Vietnam. Since very few people have been treated with tamiflu, it is not a good sign that resistance is developing so quickly.

Resistance to Amantadine and Rimantadine is universal among Vietnam and Thailand isolates (in fact they all have two resistance markers). Some other isolates (from China and Indonesia) have one marker.

The latest suggests that there have many H5N1 variants circulating in China. Most are probably sensitive to both drugs, but as the viruses become more widespread in humans, more will be treated giving rise to more resistance.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News